|
EP2508207A1
|
|
Nanoparticles loaded with chemotherapeutic antitumoral Drug
|
|
CA2794042A1
|
|
Fast dissolving drug delivery systems
|
|
WO2011070125A1
|
|
Mucoadhesive buccal tablets for the treatment of orofacial herpes
|
|
EP2368549A1
|
|
Treating hand-foot syndrome and related pathologies using clonidine or its derivatives
|
|
EP2377526A1
|
|
Fast dissolving drug delivery systems
|
|
EP2353607A1
|
|
Use of disintegrin domain of an adamalysin for the treatment of psoriasis
|
|
EP2335690A1
|
|
Mucoadhesive buccal tablets for the treatment of orofacial herpes
|
|
US2011224242A1
|
|
Styrlyquinolines, their process of preparation and their therapeutic uses
|
|
WO2010010149A1
|
|
Styrylquinolines, their process of preparation and their therapeutic uses
|
|
US2009137477A1
|
|
Treatment of oropharyngeal candidiasis in cancer patients
|
|
EP2165706A1
|
|
Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
|
|
EP2153821A1
|
|
Oral formulations of camptothecin derivatives
|
|
EP2147913A1
|
|
Styrylquinolines, their process of preparation and their therapeutic uses
|
|
EP2147912A1
|
|
Styrylquinolines, their process of preparation and their therapeutic uses
|
|
EP2149557A1
|
|
Styrylquinolines, their process of preparation and their therapeutic uses
|
|
EP2050747A1
|
|
Dimers of harmol or of its derivatives and uses thereof
|
|
EP2026809A2
|
|
Reversion of malignant phenotype with 9-hydroxy ellipticine derivatives
|
|
NZ571156A
|
|
Compressed granulated mucosal bioadhesive slow release carrier for delivering active principles
|
|
EP1972332A1
|
|
Mucosal bioadhesive slow release carrier for delivering active principles
|
|
EP1970441A1
|
|
Plasmid containing a sequence encoding a disintegrin domain of metargidin (RDD)
|
